Moreover, the CYP3A4 drug metabolizing activity is also a factor influencing inter-individual variability and hence, is relevant to NAFLD patients undergoing statin therapy. The gene discussed is CYP3A4; the disease is metabolic dysfunction-associated steatotic liver disease.